T. Rowe Price Investment Management
NTLA icon

T. Rowe Price Investment Management’s Intellia Therapeutics NTLA Stock Holding History

T. Rowe Price Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-533,617
Closed -$18.6M – 561
2022
Q4 		$18.6M Sell
533,617
-852
-0.2% -$40.5K 0.01% 466
2022
Q3 		$29.9M Buy
+534,469
New +$33.2M 0.02% 407

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management's NTLA Position: Q1 2023 in Review

T. Rowe Price Investment Management sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 533,617 shares — an estimated $18.6M sold.

T. Rowe Price Investment Management first reported a position in NTLA in Q3 2022 and held it in 2 quarters. The position peaked at $29.9M in Q3 2022. 291 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • T. Rowe Price Investment Management reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 533,617 Intellia Therapeutics shares in Q1 2023, an estimated $18.6M.
  • T. Rowe Price Investment Management first reported a position in Intellia Therapeutics in Q3 2022 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Intellia Therapeutics position peaked at $29.9M in Q3 2022.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2023, filed 15 May 2023.